Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
National Institutes of Health
Classification and identifiers
- Solicitation number
- PAR-26-149
- Assistance listing (CFDA)
- 93.397
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsU.S. Territory or Possession;
About this opportunity
This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Desig...
Related opportunities
- Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)National Institutes of HealthCloses Sep 2028
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (Clinical Trial Optional)National Institutes of Health
- Promoting Cancer Surveillance Workforce, Education, and Data UseCenters for Disease Control - NCCDPHP
- Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)National Institutes of Health
- ACS Clinician Scientist Development Grant (CSDG)American Cancer SocietyCloses Dec 2026Up to $730K
- National Biomedical Research Centers (P50 Clinical Trial Optional)National Institutes of HealthUp to $11.4M